Second quarter, April-June 2025

• Net sales amounted to SEK 0.0 (0.0) million
• Earnings after financial items amounted to SEK -24.3 (-13.1) million
• Earnings per share amounted to SEK -0.01 (-0.02)

“The fact that LIB-01 acts on structures that control erection, rather than within the erectile tissue itself, is an important distinction. From a scientific perspective, these findings are highly interesting”, commented Charlotta Gauffin, Chief Scientific Officer, following the publication of new results regarding the mechanism of action.

Significant events during the quarter

• In June, it was announced that the enrolment in the ongoing phase 2a study was completed and that all participants had been dosed according to schedule. Hence, the clinical study can be completed in August and the results reported no later than three months thereafter.
• In May it was presented that studies of LIB-01’s mechanism of action show that it affects the nerves and vascular structures that interact in creating penile erection. The results demonstrate the difference from current potency drugs and the potential to change the paradigm of erectile dysfunction management.
• The proceeds from the exercise of warrants TO 6 were received in April and provided Dicot Pharma with approximately SEK 43.8 million before issue costs. TO 6 was utilized to approximately 96 percent.
• The number of shareholders increased by 31% during the quarter to 12,788.
• The Annual General Meeting on May 6 re-elected Eva Sjökvist Saers, Fredrik Buch, Mikael von Euler, Per-Göran Gillberg, and Jan-Eric Österlund as ordinary Directors of the Board with Eva Sjökvist Saers as its Chairman.

The interim report will be presented by CEO Elin Trampe and CFO Björn Petersson in a broadcast from Direkt Studio today at 10.00 CET via this link: https://youtu.be/2BjohBjTboo. The broadcast can also be viewed afterwards via the same link.